Elevation Oncology's failure to meet the minimum bid price requirement for continued listing on Nasdaq could lead to its delisting. This is a significant negative event as it reduces the liquidity of the stock, making it harder for investors to buy or sell shares. This could lead to a decrease in the stock's price.